0001168220-13-000033.txt : 20130516 0001168220-13-000033.hdr.sgml : 20130516 20130516090706 ACCESSION NUMBER: 0001168220-13-000033 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20130516 DATE AS OF CHANGE: 20130516 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ULURU INC. CENTRAL INDEX KEY: 0001168220 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 412118656 STATE OF INCORPORATION: NV FISCAL YEAR END: 0913 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-79412 FILM NUMBER: 13849625 BUSINESS ADDRESS: STREET 1: 4452 BELTWAY DRIVE CITY: ADDISON STATE: TX ZIP: 75001 BUSINESS PHONE: 214-905-5145 MAIL ADDRESS: STREET 1: 4452 BELTWAY DRIVE CITY: ADDISON STATE: TX ZIP: 75001 FORMER COMPANY: FORMER CONFORMED NAME: OXFORD VENTURES INC DATE OF NAME CHANGE: 20020225 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: IPMD GmbH CENTRAL INDEX KEY: 0001567515 IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: SCHREYVOGELGASSE 3/5 CITY: VIENNA STATE: C4 ZIP: 1010AT BUSINESS PHONE: 214-505-5145 MAIL ADDRESS: STREET 1: C/O ULURU INC. STREET 2: 4452 BELTWAY DRIVE CITY: ADDISON STATE: TX ZIP: 75001 SC 13D 1 sc13d-ipmd_051613.htm SCHEDULE 13D - IPMD GMBH 05/07/2013 sc13d-ipmd_051613.htm


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. _______)*


ULURU Inc.
(Name of Issuer)
 
Common Stock, $0.001 par value per share
(Title of Class of Securities)
 
90403T209
(CUSIP Number)
 
Terrance K. Wallberg
c/o ULURU Inc.
4452 Beltway Drive
Addison, TX 75001
(214) 905-5145
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
 
May 7, 2013
(Date of Event which Requires Filing of this Statement)
 


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  [   ]

Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See §240.13d-7 for other parties to whom copies are to be sent.

*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
 

 




CUSIP No. 90403T209
   
1.
Names of Reporting Persons.  I.R.S. Identification Nos. of above persons (entities only).
 
 
IPMD GmbH
 
2.
Check the Appropriate Box if a Member of a Group
 
(a) /  /
(b) /  /
3.
SEC Use Only
4.
Source of Funds
WC
5.
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
/  /
6.
Citizenship or Place of Organization
Austria
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
7.
  Sole Voting Power
-0-
8.
  Shared Voting Power
3,600,000
9.
  Sole Dispositive Power
-0-
10.
  Shared Dispositive Power
3,600,000
11.
Aggregate Amount Beneficially Owned
by Each Reporting Person
3,600,000
12.
Check if the Aggregate Amount in Row (11) Excludes Certain Shares
/  /
13.
Percent of Class Represented by Amount in Row (11)
23.15%
14.
Type of Reporting Person (See Instructions)
FI


 
- 2 -

 



CUSIP No. 90403T209
   
1.
Names of Reporting Persons.  I.R.S. Identification Nos. of above persons (entities only).
 
 
Helmut Kerschbaumer
 
2.
Check the Appropriate Box if a Member of a Group
 
(a) /  /
(b) /  /
3.
SEC Use Only
4.
Source of Funds
WC
5.
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
/  /
6.
Citizenship or Place of Organization
Austria
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
7.
  Sole Voting Power
-0-
8.
  Shared Voting Power
3,600,000
9.
  Sole Dispositive Power
-0-
10.
  Shared Dispositive Power
3,600,000
11.
Aggregate Amount Beneficially Owned
by Each Reporting Person
3,600,000
12.
Check if the Aggregate Amount in Row (11) Excludes Certain Shares
/  /
13.
Percent of Class Represented by Amount in Row (11)
23.15%
14.
Type of Reporting Person (See Instructions)
IN

.

 
- 3 -

 



CUSIP No. 90403T209
   
1.
Names of Reporting Persons.  I.R.S. Identification Nos. of above persons (entities only).
 
 
Klaus Kuehne
 
2.
Check the Appropriate Box if a Member of a Group
 
(a) /  /
(b) /  /
3.
SEC Use Only
4.
Source of Funds
WC
5.
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
/  /
6.
Citizenship or Place of Organization
Germany
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
7.
  Sole Voting Power
-0-
8.
  Shared Voting Power
3,600,000
9.
  Sole Dispositive Power
-0-
10.
  Shared Dispositive Power
3,600,000
11.
Aggregate Amount Beneficially Owned
by Each Reporting Person
3,600,000
12.
Check if the Aggregate Amount in Row (11) Excludes Certain Shares
/  /
13.
Percent of Class Represented by Amount in Row (11)
23.15%
14.
Type of Reporting Person (See Instructions)
IN


 
- 4 -

 




Item 1.
Security and Issuer

This statement on Schedule 13D (this “Schedule 13D”) relates to the common stock, par value $0.001 per share (“Common Stock”), of ULURU Inc., a Nevada corporation (“ULURU”).

The address of the principal executive offices of ULURU is 4452 Beltway Drive, Addison, Texas 75001.


Item 2.
Identity and Background

(a)           This Schedule 13D is being jointly filed on behalf of (i) IPMD GmbH (“IPMD”), incorporated in Austria, (ii) Helmut Kerschbaumer, and (iii) Klaus Kuehne, pursuant to a joint filing agreement attached hereto as Ex. 99.1. IPMD, Mr. Kerschbaumer, and Mr. Kuehne are sometimes collectively referred to herein as the “Reporting Persons”.

(b)           The principal executive offices of IPMD are located at, and the principal business address of Messrs. Kerschbaumer and Kuehne is, Schreyvogelgasse 3/5, Vienna, Austria  1010AT.

(c)           The principal business of IPMD is investment and pharmaceutical product licensing and distribution.  The principal occupations of Mr. Kerschbaumer and Mr. Kuehne is to serve as directors of IPMD.

(d)(e)      During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)           IPMD is incorporated in Austria.  Helmut Kerschbaumer is a citizen of Austria.  Klaus Kuehne is a citizen of Germany.


Item 3.
Source and Amount of Funds or Other Consideration

On December 21, 2012, ULURU entered into a Securities Purchase Agreement (the “Purchase Agreement”) with IPMD relating to an equity investment of $2,000,000 by IPMD for 5,000,000 shares of our Common Stock, par value $0.001 per share (the “Shares”) and warrants to purchase up to 3,000,000 shares of our Common Stock (the “Warrants”).  Under the Purchase Agreement, the purchase and sale of the Shares and Warrants is required take place at four closings over approximately twelve months.  The first two closing have occurred, with 1,000,000 Shares being purchased for $400,000 on January 3, 2013 and 1,250,000 Shares being purchased for $500,000 on May 7, 2013.  Subsequent closings of 1,500,000 Shares for $600,000 and 1,250,000 Shares for $500,000 are scheduled on September 3, 2013 and January 3, 2014, respectively.

The Warrants have a fixed exercise price of $0.60 per share, become exercisable in tranches on each of the four funding dates, and expire on the one-year anniversary of the initial closing.  The Warrants have vested with respect to 1,350,000 shares of Common Stock and, provided that IPMD complies with its obligation to purchase additional shares of Common Stock at the two subsequent closings, will vest with respect to 900,000 shares of Common Stock on September 3, 2013 and 750,000 shares of Common Stock on January 3, 2014 assuming each of the closings scheduled on such date occurs.

The source of funds used by IPMD to acquire purchase 2,250,000 shares of Common Stock and, to cause the Warrant to vest with respect to 1,350,000 shares of Common Stock, was $900,000 of working capital.

Pursuant to a covenant in the Purchase Agreement, Mr. Kerschbaumer and Mr. Kuehne were appointed as, and currently serve as, directors of ULURU.


Item 4.
Purpose of Transaction

The purpose of the Shares is for investment purposes and to provide funding to ULURU, which manufactures products distributed by an affiliate of IPMD under a license from ULURU.

None of the Reporting Persons has any present plans which relate to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D.

 
- 5 -

 



Item 5.
Interest in Securities of the Issuer

(a)           The responses of the Reporting Persons to Rows (7) through (13) of the cover pages of this Schedule 13D are incorporated herein by reference.  The Reporting Persons may be deemed to have shared beneficial ownership of, in the aggregate, 3,600,000 shares of Common Stock, representing approximately 23.15% of the outstanding Common Stock, based on 14,199,190 shares of Common Stock outstanding as of May 7, 2013.

(b)           The Reporting Persons have the shared power to vote or to direct the vote or dispose or direct the disposition of 3,600,000 shares of Common Stock.

(c)           On March 20, 2013, Messrs. Kerschbaumer and Kuehne were each granted a stock option for their services as a director of ULURU to each purchase up to an aggregate of 100,000 shares of Common Stock, subject to certain vesting requirements.  Such options do not vest within 60 days of the filing of this report. Except as disclosed in this Item 5(c) and reported on this Form 13D, none of the persons named in Item 2 above has effected any transactions in Common Stock during the past sixty days.

(d)           Not Applicable.

(e)           Not Applicable.


Item 6.
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

IPMD is the owner of 2,250,000 shares of Common Stock and a Warrant that has vested with respect to 1,350,000 shares of Common Stock.  Messrs. Kerschbaumer and Kuehne are directors of IPMD.


Item 7.
Material to Be Filed as Exhibits

Exhibit 99.1 Joint Filing Agreement dated as May 16, 2013.

 
- 6 -

 



SIGNATURES
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Dated:
May 16, 2013
IPMD GmbH
 
 
   
BY:  /s/ Helmut Kerschbaumer
 
   
Name:  Helmut Kerschbaumer
   
Its:        Director
     
     
Dated:
May 16, 2013
Helmut Kerschbaumer
 
 
   
BY:  /s/ Helmut Kerschbaumer
 
     
     
Dated:
May 16, 2013
Klaus Kuehne
 
 
 
 BY:  /s/ Klaus Kuehne
 
 

 
- 7 -

 



 
Exhibit 99.1
 
JOINT FILING AGREEMENT
 
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock of ULURU Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement on the date(s) written below.




Dated:
May 16, 2013
IPMD GmbH
 
 
   
BY:  /s/ Helmut Kerschbaumer
 
   
Name:  Helmut Kerschbaumer
   
Its:        Director
     
     
Dated:
May 16, 2013
Helmut Kerschbaumer
 
 
   
BY:  /s/ Helmut Kerschbaumer
 
     
     
Dated:
May 16, 2013
Klaus Kuehne
 
 
 
 BY:  /s/ Klaus Kuehne
 
 



 
- 8 -